Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ethinylestradiol/chlormadinone - Grunenthal

X
Drug Profile

Ethinylestradiol/chlormadinone - Grunenthal

Alternative Names: Balianca; Belara; GRT4248

Latest Information Update: 15 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Grunenthal
  • Class Alkylated estrogenic steroids; Chlorinated steroids; Hormonal contraceptives; Hormonal replacements; Norpregnatrienes; Oral contraceptives
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pregnancy
  • No development reported Acne

Most Recent Events

  • 23 May 2023 Grunenthal and Gedeon Richter entered into a market licensee to commercialize ethinylestradiol/chlormadinone for Pregnancy (Prevention) in Brazil
  • 05 Nov 2008 Grunenthal and FAES Farma agree to co-promote ethinylestradiol/chlormadinone in Spain for Contraception/Pregnancy (Prevention)
  • 13 Dec 2007 The Committee for Medicinal Products for Human Use recommends refusal of ethinylestradiol/chlormadinone for acne in women in the EU
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top